TARS — Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: $145.4 million for Q1 2026, an increase of over 85% year-over-year, driven primarily by the launch of XTENVI.
• License Fees and Collaboration Revenues: $16.7 million, including a one-time $15 million milestone from Grand Pharma for TPO3 approval in Greater China.
• Full-Year Guidance: Reiterated net product sales guidance of $670 million to $700 million, with SG&A expenses projected at $545 million to $565 million and R&D expenses at $115 million to $135 million.
• Gross Margin: Expected to be approximately 93%.

2. Strategic Updates and Business Highlights

• XTENVI Launch: Continued strong performance with increasing prescriber adoption and depth of prescribing. Nearly half of target eye care physicians (ECPs) prescribed XTENVI weekly, up 10% from Q4 2025.
• Direct-to-Consumer (DTC) Campaign: Strong ROI exceeding expectations, with high engagement metrics on the XTENVI website.
• Pipeline Development: Initiated the CALLIOPE Phase II trial for TPO5 aimed at Lyme disease prevention, with expected top-line data in 2027. Also, the CORE study for TPO4 in ocular rosacea is progressing as planned.
• Key Account Leaders (KALs): New targeted sales team expected to enhance growth by focusing on high-potential practices.

3. Forward Guidance and Outlook

• Growth Expectations: Anticipated strong growth in Q2, with a more modest third quarter, followed by robust growth in Q4, consistent with historical patterns.
• Long-Term Potential: XTENVI is expected to reach blockbuster status with a peak sales potential of $2 billion, supported by ongoing evidence generation and expanded patient identification.

4. Bad News, Challenges, or Points of Concern

• Seasonality Impact: Q1 typically experiences seasonal dynamics such as deductible resets and adverse weather, which affected patient flow and sales.
• Competitive Landscape: Ongoing developments from competitors, such as Glaukos' Phase II trial for DB, could pose challenges, although Tarsus remains confident in XTENVI's market position.
• Regulatory Pathway for TPO5: While there is interest from federal agencies to expedite the Lyme disease program, the need for a potentially large Phase III trial remains a consideration.

5. Notable Q&A Insights

• Prescription Growth: Analysts inquired about the expected growth in prescriptions for Q2, with management declining to provide specific bottle guidance but indicating confidence in achieving full-year targets.
• Retreatment Rates: Current retreatment rates are in the mid-teens, with expectations to stabilize around 20%, which is crucial for long-term revenue projections.
• Ocular Rosacea Program: Management expressed confidence in the link between Demodex mites and ocular rosacea, with FDA-aligned endpoints for the CORE study.
• DTC Conversion Rates: While specific conversion metrics were not disclosed, management indicated that improved ROI suggests an increase in patients starting therapy.

This summary encapsulates Tarsus Pharmaceuticals' strong Q1 performance, strategic initiatives, and forward-looking guidance while acknowledging potential challenges and competitive pressures in the market.